アラバマ州におけるバーキットリンパ腫の臨床試験
アラバマ州内の拠点で、バーキットリンパ腫に関する7件の研究が参加者を募集しています。
アラバマ州内の都市
公式研究テキスト（英語）
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital of Alabama, Birmingham
被験者募集中第2相
366 Days – 46 Years · 全性別 · 2026/10/02更新 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Hospital of Alabama, Birmingham
被験者募集中第2相
365 Days · 全性別 · 2026/09/25更新 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital of Alabama, Birmingham
- USA Health Strada Patient Care Center, Mobile
被験者募集中第2相
1歳〜30歳 · 全性別 · 2026/09/01更新 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospital of Alabama, Birmingham
- USA Health Strada Patient Care Center, Mobile
被験者募集中第3相
365 Days – 25 Years · 全性別 · 2026/08/25更新 · NCT03959085Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- University of Alabama at Birmingham, Birmingham
被験者募集中第1相
18歳以上 · 全性別 · 2025/11/05更新 · NCT04260022The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Children's of Alabama/University of Alabama in Birmingham(UAB), Birmingham
被験者募集中第2相
1歳〜25歳 · 全性別 · 2025/05/04更新 · NCT03509961Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Alabama at Birmingham, Birmingham
被験者募集中第1相
18歳以上 · 全性別 · 2024/11/15更新 · NCT06034275ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。